Results 21 to 30 of about 5,232 (145)
, 2018 Supplemental material, Supplementary_Figure for Glycopyrrolate/eFlow CS: The First Nebulized Long-Acting Muscarinic Antagonist Approved to Treat Chronic Obstructive Pulmonary Disease by Roy A.
Roy A. Pleasants (5709857)
core +2 more sources
Erratum: Effect of Gender on Lung Function and Patient-Reported Outcomes in Patients with COPD Receiving Nebulized Glycopyrrolate [Corrigendum]. [PDF]
Int J Chron Obstruct Pulmon Dis, 2021 Ohar JA, Ozol-Godfrey A, Goodin T, Sanjar S. Int J Chron Obstruct Pulmon Dis. 2020;15:995–1004. The authors have advised there is an error in Figure 4B on page 1000. For EXACT-RS responder rates, the OR for both genders are shown to be significant at p<0.05; however, the OR is significant only in males.
Jill A Ohar +3 more
europepmc +5 more sources
Effect of background long-acting beta2-agonist therapy on the efficacy and safety of a novel, nebulized glycopyrrolate in subjects with moderate-to-very-severe COPD. [PDF]
Int J Chron Obstruct Pulmon Dis, 2018 Phase III studies demonstrated efficacy and safety of nebulized glycopyrrolate inhalation solution (GLY) in subjects with COPD. Secondary analyses were performed to examine the effect of background long-acting beta2-agonist (LABA) use on the efficacy and safety of nebulized GLY.In two 12-week placebo-controlled studies (GOLDEN 3 and GOLDEN 4) and one ...
Kerwin EM +4 more
europepmc +6 more sources
Efficacy and safety of a novel, nebulized glycopyrrolate for the treatment of COPD: effect of baseline disease severity and age; pooled analysis of GOLDEN 3 and GOLDEN 4. [PDF]
Int J Chron Obstruct Pulmon Dis, 2019 The efficacy and safety of nebulized glycopyrrolate inhalation solution (GLY), administered twice daily (BID) via the innovative eFlow® Closed System nebulizer (PARI Pharma GmbH, Starnberg, Germany), were demonstrated in two replicate, placebo-controlled, 12-week Phase III studies (GOLDEN 3 and GOLDEN 4).
Ohar J, Tosiello R, Goodin T, Sanjar S.
europepmc +5 more sources
Comparison of nebulized glycopyrrolate and metaproterenol in chronic obstructive pulmonary disease [PDF]
European Respiratory Journal, 1996 We assessed the bronchodilating effect of glycopyrrolate (GP) and compared it with that of metaproterenol (MP), alone and in combination (GP+MP), in patients with chronic obstructive pulmonary disease (COPD). In a double-blind study, 11 patients (aged (mean +/- SD) 69 +/- 6 yrs; forced expiratory volume in one second (FEV1) 1.2 +/- 0.4 L) with stable ...
G, Tzelepis +4 more
openaire +2 more sources
Anesthesiology Research and Practice, Volume 2023, Issue 1, 2023., 2023 Background. A respiratory adverse event is one of the main causes of critical events in the perioperative period. Perioperative distress symptoms like cough and stridor have been reported to occur in patients with hyperreactive airways. Objective. This study was conducted to determine the relationship between blood eosinophil count and perioperative ...
Nari M. Lyngdoh +8 more
wiley +1 more source
In Vitro Characterization of the eFlow Closed System Nebulizer with Glycopyrrolate Inhalation Solution [PDF]
Journal of Aerosol Medicine and Pulmonary Drug Delivery, 2018 Glycopyrrolate administered by a novel, investigational eFlow® Closed System (CS) nebulizer (eFlow CS) is being evaluated for the maintenance treatment of chronic obstructive pulmonary disease (COPD). The eFlow CS is a hand-held, vibrating membrane nebulizer optimized to deliver 1 mL of glycopyrrolate solution into the lung in
Pham, Stephen +5 more
openaire +2 more sources
Clinical Case Reports, Volume 10, Issue 4, April 2022., 2022 The main advantage of IRRIS is to provide an easily identifiable landmark to aim for, particularly where the view may be suboptimal. This may enhance the chance of successful flexible bronchoscope intubation, especially when performed by non‐experts. Abstract This case report describes a patient in the ICU in need of urgent intubation, for whom video ...
Kjartan Eskjaer Hannig +4 more
wiley +1 more source
Erratum: The Effect of Baseline Rescue Medication Use on Efficacy and Safety of Nebulized Glycopyrrolate Treatment in Patients with COPD from the GOLDEN 3 and 4 Studies [Corrigendum]. [PDF]
Int J Chron Obstruct Pulmon Dis, 2020 [This corrects the article DOI: 10.2147/COPD.S242767.].
James F Donohue +3 more
europepmc +6 more sources
Treatment of Axillary hyperhidrosis
Journal of Cosmetic Dermatology, Volume 21, Issue 1, Page 62-70, January 2022., 2022 Abstract Background Axillary hyperhidrosis characterized by excessive sweating in the axillary regions is a frustrating chronic autonomic disorder leading to social embarrassment, impaired quality of life and usually associated with palmoplantar hyperhidrosis. Identifying the condition and its cause is central to the management.
Gulhima Arora +7 more
wiley +1 more source